J&J scores another PhIII win for Erleada as it continues to build a blockbuster franchise

Just under a year since J&J won approval from the FDA to start marketing Erleada (apalutamide) for non-metastatic prostate cancer, the pharma giant has now nailed down the late-stage data it needs to prove that it works in metastatic patients as well.